We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Swiss Medica, Inc. announced today that the company has received Certificates of Free Sale from the US Food and Drug Administration for its patented O24 Pain Neutralizer and O24 Fibromyalgia products.
Predix Pharmaceuticals, headquartered in Israel and Lexington, Mass., has launched Phase I clinical trials of a new drug, PRX-07034, for treating obesity and cognitive impairment associated with Alzheimer's disease or schizophrenia.
The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the NIH, has granted Vical accelerated access to $2.6 million in funding for further development of Vaxfectin, an avian influenza vaccine being developed under a grant awarded to Vical in September 2005, the company said.
India-based Ranbaxy will market Zonisamide capsules for the treatment of epilepsy in the U.S. through a partnership with Invagen Pharmaceuticals, the company announced. Zonisamide, indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, is the generic equivalent of Eisai Pharmaceutical's Zonegran.
The Department of Health said it will coordinate the supply of medicine for the treatment of leukemia patients, after the only pharmaceutical company in Taiwan that manufactures the medicine ceased its production.
Pharmaceutical company Elan is to raise the wholesale price of its multiple sclerosis treatment Tysabri following its approval by US regulators earlier this week.
After almost six years of toing and froing, the European Parliament at long last voted through a set of new safety rules last week on childrens medicines.
AstraZeneca sought to reassure investors this week by providing an update on progress made in strengthening its product pipeline, a worry for industry analysts who believe its existing products cannot underpin earnings growth for much longer.